Search
forLearn
5 / 801 resultslearn 18β-glycyrrhetinic acid
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn pyrrolidone carboxylic acid
learn EUK 134
Research
5 / 1000+ results
research New investigational drugs for androgenetic alopecia
Possible new treatments for common hair loss include drugs, stem cells, and improved transplants.
research The therapeutic potential of CRTH2/DP2 beyond allergy and asthma
CRTH2 antagonists might be useful for treating many conditions because they play a role in immune and inflammation responses.
research Hair Restoration in Androgenetic Alopecia: Looking Beyond Minoxidil, Finasteride and Hair Transplantation
Alternative treatments show promise for hair growth beyond traditional methods.
research 17beta Hydroxysteroid Dehydrogenase Type 3 Inhibitors
The document's conclusion cannot be provided because the document is not available or cannot be read.
research 396 A novel investigator global assessment score for the evaluation of keratosis pilaris
The document's conclusion cannot be provided because the content is not accessible.
Community Join
5 / 1000+ resultscommunity The Big Fat Layer / Remedies: Cetirizine
Treating hair loss with various remedies, such as Cetirizine and the Big3 complex (minoxidil, finasteride, and RU58841), which have properties like adipogenic, anti-fibrotic and anti-inflammatory. References to research studies are also included.
community Anagenic announces the launch Pyrilutamide on their website. Are you excited ?
The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.
community RU55481
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.